Clinical Data Early data for heart drug affirm Lilly’s billion-dollar bet on Verve BioPharma DiveThe base editing medicine lowered bad cholesterol levels along with a key protein, clearing the way for a Phase 2 study.CardiovascularRead full story pharminent May 26, 2026 (Last updated: May 27, 2026) BioPharma Dive The base editing medicine lowered bad cholesterol levels along with a key protein, clearing the way for a Phase 2 study. Cardiovascular Read full story Post navigation Previous: Eli Lilly to buy trio of vaccine developers in $3.8bn outlayNext: FDA delays verdict on AZ breast cancer drug Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026